help button home button Am J Pathol ASIP MEMBERSHIP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pratt, J. R.
Right arrow Articles by Sacks, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pratt, J. R.
Right arrow Articles by Sacks, S. H.
(American Journal of Pathology. 2003;163:1457-1465.)
© 2003 American Society for Investigative Pathology

Nontransgenic Hyperexpression of a Complement Regulator in Donor Kidney Modulates Transplant Ischemia/Reperfusion Damage, Acute Rejection, and Chronic Nephropathy

Julian R. Pratt*, Miriam E. Jones*, Jun Dong*, Wuding Zhou*, Paramit Chowdhury*, Richard A. G. Smith{dagger} and Steven H. Sacks*

From the Department of Renal Medicine and Transplantation,* King’s College, University of London, London; and Adprotech Limted,{dagger} Essex, United Kingdom

Complement activation during ischemia and reperfusion contributes to the development of tissue injury with severe negative impact on outcomes in transplantation. To counter the effect of complement, we present a strategy to deliver a novel complement regulator stabilized on cell surfaces within donor organs. The membrane-bound complement regulator is able to inhibit complement activation when the donor organ is revascularized and exposed to host-circulating complement. Application of this construct to donor kidneys protected transplanted tissues from ischemia/reperfusion injury and reduced the deposition of activated complement and histological signs of damage under conditions in which a nontargeted control construct was ineffective. Treatment of donor organs in this way improved graft performance in the short and long term. An analysis of the immune response in allograft recipients showed that reducing graft damage at the time of transplantation through complement regulation also modulated the alloresponse. Additionally, the results of perfusion studies with human kidneys demonstrated the feasibility of targeting endothelial and epithelial surfaces with this construct, to allow investigation in clinical transplantation.




This article has been cited by other articles:


Home page
 BloodHome page
Q. Peng, K. Li, K. Anderson, C. A. Farrar, B. Lu, R. A. G. Smith, S. H. Sacks, and W. Zhou
Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a-C3aR interaction
Blood, February 15, 2008; 111(4): 2452 - 2461.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
Y. Banz, O. M. Hess, S. C. Robson, E. Csizmadia, D. Mettler, P. Meier, A. Haeberli, S. Shaw, R. A. Smith, and R. Rieben
Attenuation of myocardial reperfusion injury in pigs by Mirococept, a membrane-targeted complement inhibitor derived from human CR1
Cardiovasc Res, December 1, 2007; 76(3): 482 - 493.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. E. Bowles, I. Wilkinson, R. A. G. Smith, A. J. G. Moir, H. Montgomery, and R. J. M. Ross
Membrane Reinsertion of a Myristoyl-Peptidyl Anchored Extracellular Domain Growth Hormone Receptor
Endocrinology, February 1, 2007; 148(2): 824 - 830.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
H. Patel, R. A.G. Smith, S. H. Sacks, and W. Zhou
Therapeutic Strategy with a Membrane-Localizing Complement Regulator to Increase the Number of Usable Donor Organs after Prolonged Cold Storage
J. Am. Soc. Nephrol., April 1, 2006; 17(4): 1102 - 1111.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Hill, S. H. Ridley, D. Esser, R. G. Oldroyd, M. J. Cullen, P. Kareclas, S. Gallagher, G. P. Smith, S. J. Richards, J. White, et al.
Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy
Blood, March 1, 2006; 107(5): 2131 - 2137.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
C. A. Farrar, W. Zhou, T. Lin, and S. H. Sacks
Local extravascular pool of C3 is a determinant of postischemic acute renal failure
FASEB J, February 1, 2006; 20(2): 217 - 226.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. P. Berger, A. Roos, and M. R. Daha
Complement and the kidney: What the nephrologist needs to know in 2006?
Nephrol. Dial. Transplant., December 1, 2005; 20(12): 2613 - 2619.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
Y. Banz, O. M. Hess, S. C. Robson, D. Mettler, P. Meier, A. Haeberli, E. Csizmadia, E. Y. Korchagina, N. V. Bovin, and R. Rieben
Locally targeted cytoprotection with dextran sulfate attenuates experimental porcine myocardial ischaemia/reperfusion injury
Eur. Heart J., November 1, 2005; 26(21): 2334 - 2343.
[Abstract] [Full Text] [PDF]

Home page
 Protein Sci.Home page
J. White, P. Lukacik, D. Esser, M. Steward, N. Giddings, J. R. Bright, S. J. Fritchley, B. P. Morgan, S. M. Lea, G. P. Smith, et al.
Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli
Protein Sci., September 1, 2004; 13(9): 2406 - 2415.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Society for Investigative Pathology.